Talk:Moxetumomab pasudotox
| This is the talk page for discussing improvements to the Moxetumomab pasudotox article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
It is of interest to the following WikiProjects:
| This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks. | |
| Mid | This article has been rated as Mid-importance on the project's importance scale. | |
| This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine. | |
| Mid | This article has been rated as Mid-importance on the project's importance scale. | |
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Moxetumomab pasudotox.
|
Could add a Mechanism section[edit]
eg to say that it targets B-cells to kill them. - Rod57 (talk) 10:47, 25 September 2018 (UTC)